Literature DB >> 16386240

The role of interleukin-12 in the pathogenesis of psoriasis.

Olfat G Shaker1, Wedad Moustafa, Samia Essmat, Mona Abdel-Halim, Mohamed El-Komy.   

Abstract

OBJECTIVES: To verify the role of IL-12 in the pathogenesis of psoriasis and determine its relation to IFNgamma. DESIGN AND METHODS: Skin biopsies from lesional and non-lesional skin of 30 patients and 10 healthy controls were obtained for quantitative PCR examination of IL-12 (P40) and IFNgamma mRNA as well as in situ PCR of IL-12 (P40) and IFNgamma mRNA.
RESULTS: IL-12 and IFNgamma levels were higher in lesional skin than in non-lesional and control skin. A significant correlation between IL-12 and IFNgamma was found. By in situ PCR hybridization, IL-12 expression was only found in the dermis, while IFNgamma was invariably expressed in the dermis and/or epidermis.
CONCLUSION: We suggest that IL-12 independently and through IFNgamma induction may have a crucial role in the development of the active psoriatic lesion itself, where it is probably produced locally in the dermis as a step in the evolution of the psoriatic lesion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16386240     DOI: 10.1016/j.clinbiochem.2005.11.008

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

Review 1.  Immunobiologics in the treatment of psoriasis.

Authors:  Benjamin F Chong; Henry K Wong
Journal:  Clin Immunol       Date:  2007-02-21       Impact factor: 3.969

2.  Genetic polymorphisms of NFκB1 -94 del/ins ATTG, NFκB1A 2758 A>G and SUMO rs237025 G>A in psoriasis.

Authors:  Abdullateef A Alzolibani; Ahmed Settin; Ahmed Ali Ahmed; Hisham Ismail; Noor Elhefni; Ahmad A Al Robaee
Journal:  Int J Health Sci (Qassim)       Date:  2015-01

Review 3.  Interleukin-23: as a drug target for autoimmune inflammatory diseases.

Authors:  Chunlei Tang; Shu Chen; Hai Qian; Wenlong Huang
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

Review 4.  Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.

Authors:  Jie Wang; Yow-Ming C Wang; Hae-Young Ahn
Journal:  AAPS J       Date:  2014-07-04       Impact factor: 4.009

Review 5.  Ustekinumab.

Authors:  Oya Cingoz
Journal:  MAbs       Date:  2009 May-Jun       Impact factor: 5.857

6.  Inhibitory effect of a standardized pomegranate fruit extract on Wnt signalling in 1, 2-dimethylhydrazine induced rat colon carcinogenesis.

Authors:  Nermin Abdel Hamid Sadik; Olfat Gamil Shaker
Journal:  Dig Dis Sci       Date:  2013-05-31       Impact factor: 3.199

7.  Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement.

Authors:  Eric Toussirot; Fabrice Michel; Matthieu Béreau; Delphine Binda
Journal:  Patient Prefer Adherence       Date:  2013-04-26       Impact factor: 2.711

8.  An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis.

Authors:  Magdalena Kutwin; Monika Migdalska-Sęk; Ewa Brzeziańska-Lasota; Piotr Zelga; Anna Woźniacka
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.